{"protocolSection": {"identificationModule": {"nctId": "NCT02840799", "orgStudyIdInfo": {"id": "824290"}, "organization": {"fullName": "University of Pennsylvania", "class": "OTHER"}, "briefTitle": "Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)", "officialTitle": "Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)"}, "statusModule": {"statusVerifiedDate": "2023-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-08"}, "primaryCompletionDateStruct": {"date": "2022-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-06-13", "studyFirstSubmitQcDate": "2016-07-18", "studyFirstPostDateStruct": {"date": "2016-07-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2023-07-27", "resultsFirstSubmitQcDate": "2023-12-14", "resultsFirstPostDateStruct": {"date": "2023-12-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-12-14", "lastUpdatePostDateStruct": {"date": "2023-12-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Pennsylvania", "class": "OTHER"}, "collaborators": [{"name": "Northwestern University", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This trial seeks to assess if potassium nitrate (KNO3) therapy improves exercise capacity and oxygen uptake in heart failure patients with preserved ejection fraction (HFpEF).", "detailedDescription": "Approximately 50% of heart failure patients exhibit preserved left ventricular (LV) ejection fraction (EF), and therefore have HF with preserved EF (HFpEF). There are currently no proven effective pharmacologic interventions. Exercise intolerance with reduced aerobic capacity is the hallmark of HFpEF and greatly impairs quality of life (QOL). During exercise, blood vessels within active muscle vasodilator, increasing perfusion to the muscle bed. Nitric oxide is a chief mediator of this process. Inorganic nitrate can ultimately be converted to nitric oxide. This conversion occurs preferentially at the site of exercising muscle, allowing for vasodilation to occur, hence increasing blood flow to the working muscle. Preliminary data suggest that inorganic nitrate improves exercise tolerance in HFpEF. The investigator will aim to test this hypothesis in a larger group."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["Heart Failure", "Exercise Intolerance", "Ejection Fraction"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 84, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Potassium Nitrate (KNO3)", "type": "EXPERIMENTAL", "description": "Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.", "interventionNames": ["Drug: Potassium Nitrate (KNO3)"]}, {"label": "Potassium Chloride (KCl)", "type": "PLACEBO_COMPARATOR", "description": "Potassium Chloride (KCl) is the placebo (control drug) in this trial.\n\nPotassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.", "interventionNames": ["Drug: Potassium Chloride (KCl)"]}], "interventions": [{"type": "DRUG", "name": "Potassium Nitrate (KNO3)", "description": "The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed.", "armGroupLabels": ["Potassium Nitrate (KNO3)"]}, {"type": "DRUG", "name": "Potassium Chloride (KCl)", "description": "Potassium Chloride (KCl) is the matching placebo control drug in this trial.", "armGroupLabels": ["Potassium Chloride (KCl)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Difference in Peak Oxygen Consumption (Vo2) Between KNO3 and KCl Phases", "description": "Subjects will perform a maximal-effort peak oxygen consumption test using a supine bicycle exercise test with expired gas analysis.", "timeFrame": "6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)"}, {"measure": "Change in Total Work Performed During a Maximal-effort Exercise Test From Phase 1 to Phase 2", "description": "Subjects will perform a maximal-effort supine bicycle exercise test.", "timeFrame": "6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)"}], "secondaryOutcomes": [{"measure": "Effect of Potassium Nitrate (KNO3) on Quality of Life (QOL)", "description": "QOL will be assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ). The overall summary score from the KCCQ ranges from 0-100, where higher scores indicate a better quality of life.", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)"}, {"measure": "Effect of KNO3 on the Percent Change of Systemic Vasodilatory Response to Exercise: The Change in Systemic Vascular Resistance Reserve During Exercise During a Maximal Effort Exercise Test", "description": "We measured the Systematic vasodilatory response at rest and peak maximal exercise using corresponding echo parameters and blood pressures for each visit. This measure depicts the change from rest and exercise.", "timeFrame": "6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)"}, {"measure": "Effect of Potassium Nitrate (KNO3) on Muscle Phosphocreatine (PCr) Recovery Kinetics Following a Standardized Plantar Flexor Exercise Protocol", "description": "Muscle PCr recovery kinetics were measured using MRI and a standardized plantar flexor exercise protocol with a high resolution spatial mapping of creatine in muscle to analyze creatine chemical exchange saturation transfer and quantify the recovery kinetics of creatine levels. Exercise induces increases in the rate of O2 consumption, which upon cessation of exercise, declines towards baseline in a mono-exponential fashion. This is characterized by a time constant (\u03c4, tau) that corresponds to the time constant of PCr recovery kinetics. Muscle PCr is a marker of oxidative capacity. This outcome measure relates to the half-time derived from linear regression, where a lower value depicts a faster PCr recovery.", "timeFrame": "6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)"}, {"measure": "Effect of Potassium Nitrate (KNO3) on Left Ventricle (LV) Diastolic Function: E/e' Ratio", "description": "E/e' ratio is a standard echo parameter that was measured at rest during each visit and calculated using the mitral E, septal e', and lateral e'. This index is parameter for noninvasive left ventricular diastolic function assessment, where an E/e' ratio \\< 8 is considered to be normal, and a ratio \\> 15 is considered to reflect an increase in the LV filling pressure.", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)"}, {"measure": "Effect of Potassium Nitrate (KNO3) on Left Ventricle (LV) Diastolic Function: Left Atrial Volume Index", "description": "Left atrial volume index is a standard echo parameter that was measured at rest during each visit and calculated the body surface area (Dubois and Dubois equation) and left atrial volume from both the two chamber and four chamber views.", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)"}, {"measure": "Effect of Potassium Nitrate (KNO3) on Myocardial Systolic Strain: Peak Global Systolic Myocardial Longitudinal Strain", "description": "Peak global systolic myocardial longitudinal strain was evaluated with resting echocardiograms at each visit. Strain was analyzed at the four chamber, two chamber, and three chamber views of the left ventricle and averaged.", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)"}, {"measure": "Effect of Potassium Nitrate (KNO3) on Late Systolic Wall Stress as Assessed by the Arts Formula Using Echocardiographic and Tonometry Recordings", "description": "Late systolic wall stress is assessed via comprehensive aortic pressure-flow relations, using arterial tonometry and Doppler echocardiography. Myocardial wall stress was calculated with the following formula =: Stress = P / \\[1/3 In (1 + VW/VLV)\\], where ln is the natural logarithm, P is aortic pressure obtained with arterial tonometry, VW is the volume of the LV wall obtained with echocardiography and VLV is the cavity volume obtained with echocardiography", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)"}, {"measure": "Effect of Potassium Nitrate (KNO3) on Arterial Wave Reflections as Assessed by Wave Separation Analysis Using Tonometry and Doppler Flow Data", "description": "Arterial Wave reflections were assessed via wave separation analysis, using arterial tonometry and Doppler echocardiography.\n\nThe pulse wave generated by the left ventricle travels forward in arteries and is partially reflected at sites of impedance mismatch (i.e., bifurcations, points of change in arterial size or wall stiffness, predominantly in middle-sized conduit arteries). Wave reflections travel back to the heart, merging into a discrete reflected wave and arrive while the LV is still ejecting blood in mid-to-late systole. Wave reflections increase the late systolic workload of the LV and profoundly impact the LV loading sequence (late relative to early systolic load).", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)"}, {"measure": "Effect of Potassium Nitrate (KNO3) on Augmentation Index", "description": "Aortic augmentation index was assessed via comprehensive aortic pressure-flow relations, using arterial tonometry and Doppler echocardiography. It is an indirect measure of arterial stiffness, where a higher value would indicate greater arterial stiffness risk.", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)"}, {"measure": "Effect of Potassium Nitrate (KNO3) on Muscle Blood Flow During Exercise: Muscle Blood Flow During Exercise, Measured With Arterial MRI Spin Labeling During a Standardized Plantar Flexion Exercise Test", "description": "MRI studies will be performed at rest and immediately after a standardized plantar flexion exercise. Arterial spin labeling using the flow-sensitive alternating inversion recovery (FAIR) technique will be used to image muscle perfusion with high temporal resolution.", "timeFrame": "6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)"}, {"measure": "Effect of Potassium Nitrate (KNO3) on Myocardial Systolic Strain: Peak Global Systolic Myocardial Circumferential Strain", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Adults aged 18-90 years of age\n2. A diagnosis of heart failure with NYHA Class II-III symptoms\n3. LV ejection fraction \\>50% during baseline echocardiography\n4. Stable medical therapy: no addition/removal/changes in antihypertensive medications, or beta-blockers in the preceding 30 days\n5. Elevated filling pressures as evidenced by at least 1 of the following:\n\n   1. Mitral E/e' ratio \\> 8 (either lateral or septal), with low e' velocity (septal e'\\<7 cm/sec or lateral e'\\< 10 cm/sec), in addition to one of the following:\n\n      i Enlarged left atrium (LA volume index \\>34 ml/m2) ii Chronic loop diuretic use for control of symptoms iii Elevated natriuretic peptides (BNP levels \\>100 ng/L or NT-proBNP levels \\>300 ng/L)\n   2. Mitral E/e' ratio \\> 14 (either lateral or septal)\n   3. Elevated invasively-determined filling pressures previously (resting LVEDP\\>16 mmHg or mean pulmonary capillary wedge pressure \\[PCWP\\] \\> 12 mmHg; or PCWP/LVEDP\u226525 mmHg with exercise)\n   4. Acute heart failure decompensation requiring IV diuretics\n\nExclusion Criteria:\n\n1. Supine systolic blood pressure \\<100 mm Hg\n2. Pregnancy: Women of childbearing potential will undergo a pregnancy test during the screening visit\n3. Orthostatic hypotension defined as \\>20 mm Hg decrease in systolic blood pressure 3-5 minutes following the transition from the supine to standing position\n4. Uncontrolled atrial fibrillation, as defined by a resting heart rate\\>100 beats per minute\n5. Hemoglobin \\< 10 g/dL\n6. Inability/unwillingness to exercise\n7. Moderate or greater left sided valvular disease (mitral regurgitation, aortic stenosis, aortic regurgitation), any degree of mitral stenosis, severe right-sided valvular disease, or presence of a prosthetic valve in the mitral position\n8. Hypertrophic, infiltrative, or inflammatory cardiomyopathy\n9. Clinically significant pericardial disease, as per investigator judgement.\n10. Current angina\n11. Acute coronary syndrome or coronary intervention within the past 2 months\n12. Primary pulmonary arteriopathy\n13. Clinically significant lung disease as defined by: Chronic Obstructive Pulmonary Disease meeting Stage III or greater GOLD criteria, treatment with oral steroids within the past 6 months for an exacerbation of obstructive lung disease, or the use of daytime supplemental oxygen\n14. Ischemia on stress testing without either (1) subsequent revascularization, or; (2) a subsequent angiogram demonstrating the absence of clinically significant epicardial coronary artery disease, as per investigator judgement.\n15. Left ventricular ejection fraction \\<45% in any prior echocardiogram or cardiac MRI, unless this was in the setting of uncontrolled atrial fibrillation.\n16. Treatment with phosphodiesterase inhibitors that cannot be withheld\n17. Treatment with organic nitrates\n18. Significant liver disease impacting synthetic function or volume control (ALT/AST \\> 3x ULN, Albumin \\<3.0 g/dL)\n19. eGFR \\< 30 mL/min/1.73m2\n20. G6PD deficiency. In males of African, Asian or Mediterranean decent, this will be formally evaluated by enzyme testing prior to drug administration. A negative screening test for G6PD will be required in these subjects for inclusion in the study. If a quantitative test is being performed, a clinically significant reduction in G6PD activity (\\<60% of normal) will exclude subjects.\n21. Methemoglobinemia - baseline methemoglobin level \\>5%\n22. Serum K\\>5.0 mEq/L\n23. Severe right ventricular dysfunction\n24. Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the study.\n25. Contraindications to MRI (except as noted below), including the presence of a pacemaker, metal implants, claustrophobia, or that have known medical conditions which can be exacerbated by stress such as anxiety or panic attacks. Inability to lie flat in the MRI scanner for 90 minutes is also an exclusion criterion.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "90 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Julio A Chirinos, MD, PhD", "affiliation": "University of Pennsylvania", "role": "STUDY_CHAIR"}, {"name": "Payman Zamani, MD", "affiliation": "University of Pennsylvania", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Sanjiv Shah, MD", "affiliation": "Northwestern University", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Sujith Kuruvilla, MD", "affiliation": "Corporal Michael J Crescenz Veterans Affairs Medical Center (VA)", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Northwestern Medical Center", "city": "Evanston", "state": "Illinois", "zip": "60208", "country": "United States", "geoPoint": {"lat": 42.04114, "lon": -87.69006}}, {"facility": "Corporal Michael J Crescenz Veterans Affairs Medical Center (VA)", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Hospital of the University of Pennsylvania", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Following the endpoint assessment of the first phase, subjects will enter a 1-week washout period during which they will not receive any study medications.", "groups": [{"id": "FG000", "title": "Potassium Nitrate (KNO3), Then Potassium Chloride (KCl)", "description": "Potassium nitrate (KNO3) capsules, provided 6 millimoles of inorganic nitrate per capsule, and was taken three times daily for 6 weeks.\n\nAfter a one week washout period, participants crossed over to take Potassium Chloride.\n\nPotassium Chloride (KCl) capsules was administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial."}, {"id": "FG001", "title": "Potassium Chloride (KCl) Then Potassium Nitrate (KNO3)", "description": "Potassium Chloride (KCl) capsules was administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial.\n\nPotassium Nitrate (KNO3) capsules, provided 6 millimoles of inorganic nitrate per capsule, and was taken three times daily for 6 weeks.\n\nAfter a one week washout period, participants crossed over to take Potassium Nitrate."}], "periods": [{"title": "Phase 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "41"}, {"groupId": "FG001", "numSubjects": "43"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "40"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Phase 2 (Crossover)", "milestones": [{"type": "STARTED", "comment": "Nine participants did not cross over due to dispensing error. The subjects received the same treatment that was originally dispensed during Period 1/Phase 1.", "achievements": [{"groupId": "FG000", "numSubjects": "41"}, {"groupId": "FG001", "numSubjects": "35"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "41"}, {"groupId": "FG001", "numSubjects": "33"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Experimental: Potassium Nitrate (KNO3) Then Potassium Chloride (KCl)", "description": "Participants were randomized and first received potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks. Potassium nitrate is the active drug in this trial.\n\nAfter a washout period of 1 week, participant crossed over to receive potassium chloride (KCl), the matching placebo (control drug) in this trial. Potassium Chloride (KCl) capsules were administered at a dose of 6 millimoles (1 capsule) three times daily for 6 week."}, {"id": "BG001", "title": "Experimental: Potassium Chloride (KCl) Then Potassium Nitrate (KNO3)", "description": "Participants were randomized and first received potassium chloride (KCl), the matching placebo (control drug) in this trial. Potassium Chloride (KCl) capsules were administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nAfter a washout period of 1 week, participants cross over to receive potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "84"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "69.7", "spread": "7.55"}, {"groupId": "BG001", "value": "67.7", "spread": "11.2"}, {"groupId": "BG002", "value": "68.7", "spread": "9.58"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "58"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "26"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Black", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "20"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "64"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "84"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "35.3", "spread": "7.89"}, {"groupId": "BG001", "value": "37.1", "spread": "7.86"}, {"groupId": "BG002", "value": "36.2", "spread": "7.88"}]}]}]}, {"title": "Current Smoker", "description": "Medical history was obtained via medical chart review and participant self-reporting. Smoking status was obtained as part of their social history.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Yes", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "No", "measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "84"}]}]}]}, {"title": "Former smoker", "description": "Medical history was obtained via medical chart review and participant self-reporting. Smoking status was obtained as part of their social history.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Yes", "measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "38"}]}, {"title": "No", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "46"}]}]}]}, {"title": "Prior Acute Coronary Syndrome or Myocardial infarction", "description": "For all participants, past medical history was obtained using chart review and participant self-reports.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "7"}]}]}]}, {"title": "Prior Angina", "description": "For all participants, past medical history was obtained using chart review and participant self-reports.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "14"}]}]}]}, {"title": "Prior Arrythmia", "description": "For all participants, past medical history was obtained using chart review and participant self-reports. Any arrhythmia would be included in this category.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "32"}]}]}]}, {"title": "Prior significant valvular disease or valve surgery in the past", "description": "For all participants, past medical history was obtained using chart review and participant self-reports.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Hypertension", "description": "For all participants, past medical history was obtained using chart review and participant self-reports.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "72"}]}]}]}, {"title": "High Cholesterol", "description": "For all participants, past medical history was obtained using chart review and participant self-reports.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "60"}]}]}]}, {"title": "Peripheral vascular disease", "description": "For all participants, past medical history was obtained using chart review and participant self-reports. Peripheral vascular disease included carotid, aortic, or femoral stenosis or history of claudications.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}]}]}, {"title": "Diabetes", "description": "For all participants, past medical history was obtained using chart review and participant self-reports.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "38"}]}]}]}, {"title": "Prior CVA/TIA", "description": "For all participants, past medical history was obtained using chart review and participant self-reports.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}]}]}, {"title": "Prior Pulmonary embolism/DVT", "description": "For all participants, past medical history was obtained using chart review and participant self-reports.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "6"}]}]}]}, {"title": "Obstructive sleep apnea (OSA)", "description": "For all participants, past medical history was obtained using chart review and participant self-reports.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Obstructive sleep apnea (OSA)", "categories": [{"measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "46"}]}]}, {"title": "CPAP Use", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "34"}]}]}]}, {"title": "COPD/Asthma", "description": "For all participants, past medical history was obtained using chart review and participant self-reports.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "25"}]}]}]}, {"title": "Prior CABG", "description": "For all participants, past medical history was obtained using chart review and participant self-reports.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}]}]}, {"title": "Osteoarthritis", "description": "For all participants, past medical history was obtained using chart review and participant self-reports.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "37"}]}]}]}, {"title": "NYHA Class", "description": "The NYHA (New York Heart Association) classification system was used to classify participant symptoms during the baseline visit by study team.\n\nThe following symptoms were assessed: orthopnea, paroxysmal nocturnal dyspnea, lower extremity edema, dyspnea upon exertion, and walking distance before stopping.\n\nWith these symptoms, participants were then classified into the following NYHA classes:\n\nNYHA Class I = no symptoms NYHA Class II = symptoms with significant exertion NYHA Class III = symptoms with mild exertion NYHA Class IV = symptoms occur at rest", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "I", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "II", "measurements": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "58"}]}, {"title": "III", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "26"}]}, {"title": "IV", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Systolic Blood Pressure", "description": "The baseline physical exam measured all vital signs.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "130", "spread": "16.9"}, {"groupId": "BG001", "value": "133", "spread": "17.4"}, {"groupId": "BG002", "value": "132", "spread": "17.1"}]}]}]}, {"title": "Diastolic Pressure", "description": "The baseline physical exam measured all vital signs.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "74.7", "spread": "8.97"}, {"groupId": "BG001", "value": "74.7", "spread": "10.2"}, {"groupId": "BG002", "value": "74.7", "spread": "9.58"}]}]}]}, {"title": "Blood Oxygen Saturation", "description": "The baseline physical exam measured all vital signs.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent (%) oxygen saturation", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "97.4", "spread": "1.23"}, {"groupId": "BG001", "value": "97.5", "spread": "1.40"}, {"groupId": "BG002", "value": "97.5", "spread": "1.31"}]}]}]}, {"title": "6 Minute Walk Test: Total Meters Walk", "description": "At the baseline visit, 6 minute walk tests were performed.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "meters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "338", "spread": "102"}, {"groupId": "BG001", "value": "333", "spread": "94.2"}, {"groupId": "BG002", "value": "336", "spread": "97.3"}]}]}]}, {"title": "Kansas City Cardiomyopathy Questionnaire (KCCQ) Results", "description": "KCCQ surveys were provided to participants at baseline, phase 1 visit, and phase 2 visit and scored according to KCCQ guidelines. The surveys were then scored using KCCQ guidelines, in which KCCQ scores range from 0-100, where a lower score indicates more severe symptoms/limitations and 100 indicates no symptoms.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "scores on a scale of 0-100", "classes": [{"title": "Physical Limitations Score", "categories": [{"measurements": [{"groupId": "BG000", "value": "67.3", "spread": "16.2"}, {"groupId": "BG001", "value": "62.0", "spread": "22.7"}, {"groupId": "BG002", "value": "64.6", "spread": "19.9"}]}]}, {"title": "Symptom Stability Score", "categories": [{"measurements": [{"groupId": "BG000", "value": "50.6", "spread": "14.2"}, {"groupId": "BG001", "value": "52.3", "spread": "17.1"}, {"groupId": "BG002", "value": "51.5", "spread": "15.7"}]}]}, {"title": "Symptom Frequency Score", "categories": [{"measurements": [{"groupId": "BG000", "value": "69.0", "spread": "21.3"}, {"groupId": "BG001", "value": "62.2", "spread": "24.2"}, {"groupId": "BG002", "value": "65.5", "spread": "22.9"}]}]}, {"title": "Sympton Burden Score", "categories": [{"measurements": [{"groupId": "BG000", "value": "69.7", "spread": "20.4"}, {"groupId": "BG001", "value": "63.6", "spread": "21.4"}, {"groupId": "BG002", "value": "66.6", "spread": "21"}]}]}, {"title": "Total Symptom Score", "categories": [{"measurements": [{"groupId": "BG000", "value": "69.3", "spread": "19.6"}, {"groupId": "BG001", "value": "62.9", "spread": "21"}, {"groupId": "BG002", "value": "66", "spread": "20.5"}]}]}, {"title": "Self-efficacy Score", "categories": [{"measurements": [{"groupId": "BG000", "value": "80.2", "spread": "22"}, {"groupId": "BG001", "value": "76.5", "spread": "30.3"}, {"groupId": "BG002", "value": "78.3", "spread": "26.5"}]}]}, {"title": "Quality of Life Score", "categories": [{"measurements": [{"groupId": "BG000", "value": "65.0", "spread": "22.1"}, {"groupId": "BG001", "value": "56.8", "spread": "25.8"}, {"groupId": "BG002", "value": "60.8", "spread": "24.3"}]}]}, {"title": "Social Limitation Summary Score", "categories": [{"measurements": [{"groupId": "BG000", "value": "57.9", "spread": "27.5"}, {"groupId": "BG001", "value": "52.7", "spread": "23.1"}, {"groupId": "BG002", "value": "55.3", "spread": "25.4"}]}]}, {"title": "Overall Score", "categories": [{"measurements": [{"groupId": "BG000", "value": "64.9", "spread": "14.9"}, {"groupId": "BG001", "value": "58.1", "spread": "18.4"}, {"groupId": "BG002", "value": "61.4", "spread": "17"}]}]}, {"title": "Clinical Summary Score", "categories": [{"measurements": [{"groupId": "BG000", "value": "68.3", "spread": "14"}, {"groupId": "BG001", "value": "62.4", "spread": "18.5"}, {"groupId": "BG002", "value": "65.3", "spread": "16.6"}]}]}]}, {"title": "Current Medications", "description": "Current medications were obtained via medical chart review and participant self-reporting.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "ACE Inhibitors", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "20"}]}]}, {"title": "Angiotensin Receptor Blockers (ARB)", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "31"}]}]}, {"title": "Calcium Channel Blockers (CCB)", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "30"}]}]}, {"title": "Beta Blockers", "categories": [{"measurements": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "47"}]}]}, {"title": "Diuretics", "categories": [{"measurements": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "73"}]}]}, {"title": "Statins", "categories": [{"measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "57"}]}]}, {"title": "Anti Arrythmia", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "Anti Coagulation", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Anti Platelet", "categories": [{"measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "57"}]}]}, {"title": "Insulin", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "13"}]}]}]}, {"title": "eGFR", "description": "eGFR was calculated with the 2009 CKD-EPI creatinine equation by study team. The creatinine lab results were processed during study visits.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/min/1.73m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "66.4", "spread": "16.6"}, {"groupId": "BG001", "value": "70.6", "spread": "18.7"}, {"groupId": "BG002", "value": "68.5", "spread": "17.7"}]}]}]}, {"title": "Methemeglobin", "description": "During the baseline visit, participants consented to a co-oximetry blood panel, and the processing lab provided the resulting levels.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent in blood", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.729", "spread": "0.593"}, {"groupId": "BG001", "value": "0.642", "spread": "0.379"}, {"groupId": "BG002", "value": "0.685", "spread": "0.494"}]}]}]}, {"title": "Oxyhemoglobin", "description": "During the baseline visit, participants consented to a co-oximetry blood panel, and the processing lab provided the resulting levels.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent in blood", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "78.5", "spread": "12.9"}, {"groupId": "BG001", "value": "77.4", "spread": "16.7"}, {"groupId": "BG002", "value": "77.9", "spread": "14.8"}]}]}]}, {"title": "Carboxyhemoglobin", "description": "During the baseline visit, participants consented to a co-oximetry blood panel, and the processing lab provided the resulting levels.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent in blood", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.82", "spread": "0.3777"}, {"groupId": "BG001", "value": "1.67", "spread": "0.354"}, {"groupId": "BG002", "value": "1.75", "spread": "0.370"}]}]}]}, {"title": "O2 Count", "description": "During the baseline visit, participants consented to a co-oximetry blood panel, and the processing lab provided the resulting levels.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14.5", "spread": "2.64"}, {"groupId": "BG001", "value": "15.1", "spread": "3.96"}, {"groupId": "BG002", "value": "14.8", "spread": "3.36"}]}]}]}, {"title": "Hemoglobin", "description": "During the baseline visit, participants consented to a co-oximetry blood panel, and the processing lab provided the resulting levels.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "13.4", "spread": "1.48"}, {"groupId": "BG001", "value": "13.6", "spread": "1.18"}, {"groupId": "BG002", "value": "13.5", "spread": "1.33"}]}]}]}, {"title": "NT Pro-BNP", "description": "A sample was collected as part of visit labs and processed by our clinical laboratory for NT ProBNP", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "pg/mL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "263", "spread": "332"}, {"groupId": "BG001", "value": "213", "spread": "359"}, {"groupId": "BG002", "value": "238", "spread": "344"}]}]}]}, {"title": "Ejection Fraction", "description": "A baseline echocardiogram was performed and quantified.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent total blood", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "61.8", "spread": "3.92"}, {"groupId": "BG001", "value": "61.2", "spread": "3.57"}, {"groupId": "BG002", "value": "61.5", "spread": "3.74"}]}]}]}, {"title": "Left Atrial Volume Index", "description": "A baseline echocardiogram was performed and quantified.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28.4", "spread": "9.45"}, {"groupId": "BG001", "value": "26.5", "spread": "8.40"}, {"groupId": "BG002", "value": "27.4", "spread": "8.93"}]}]}]}, {"title": "Septal E/e' Ratio", "description": "A baseline echocardiogram was performed and quantified.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Ratio", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14", "spread": "5.79"}, {"groupId": "BG001", "value": "13.3", "spread": "5.39"}, {"groupId": "BG002", "value": "13.6", "spread": "5.56"}]}]}]}, {"title": "Lateral E/e' Ratio", "description": "A baseline echocardiogram was performed and quantified.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Ratio", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10.1", "spread": "3.50"}, {"groupId": "BG001", "value": "11.3", "spread": "5.34"}, {"groupId": "BG002", "value": "10.7", "spread": "4.55"}]}]}]}, {"title": "Septal Lateral Mean E/e' Ratio", "description": "A baseline echocardiogram was performed and quantified.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Ratio", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "11.5", "spread": "4.07"}, {"groupId": "BG001", "value": "12.1", "spread": "4.90"}, {"groupId": "BG002", "value": "11.8", "spread": "4.49"}]}]}]}, {"title": "White Blood Cells", "description": "A CBC panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "THO/uL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6.68", "spread": "2.01"}, {"groupId": "BG001", "value": "7.41", "spread": "1.53"}, {"groupId": "BG002", "value": "7.06", "spread": "1.81"}]}]}]}, {"title": "Red Blood Cells", "description": "A CBC panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "MIL/uL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.52", "spread": "0.525"}, {"groupId": "BG001", "value": "4.56", "spread": "0.383"}, {"groupId": "BG002", "value": "4.54", "spread": "0.455"}]}]}]}, {"title": "Hemoglobin", "description": "A CBC panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "13.2", "spread": "1.42"}, {"groupId": "BG001", "value": "13.4", "spread": "1.15"}, {"groupId": "BG002", "value": "13.3", "spread": "1.28"}]}]}]}, {"title": "Hematocrit", "description": "A CBC panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent of blood", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "39.8", "spread": "4.23"}, {"groupId": "BG001", "value": "40.5", "spread": "2.98"}, {"groupId": "BG002", "value": "40.1", "spread": "3.63"}]}]}]}, {"title": "RDW (red blood cell distribution width)", "description": "A CBC panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent red blood cells", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14.3", "spread": "1.51"}, {"groupId": "BG001", "value": "14.4", "spread": "1.31"}, {"groupId": "BG002", "value": "14.3", "spread": "1.40"}]}]}]}, {"title": "MCH (mean corpuscular hemoglobin)", "description": "A CBC panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "pg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29.4", "spread": "2.74"}, {"groupId": "BG001", "value": "19.3", "spread": "2.00"}, {"groupId": "BG002", "value": "19.4", "spread": "2.37"}]}]}]}, {"title": "MCHC (mean corpuscular hemoglobin concentration)", "description": "A CBC panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.1", "spread": "0.952"}, {"groupId": "BG001", "value": "33.1", "spread": "0.930"}, {"groupId": "BG002", "value": "33.1", "spread": "0.935"}]}]}]}, {"title": "MCV (mean corpuscular volume)", "description": "A CBC panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "fL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "88.6", "spread": "7.40"}, {"groupId": "BG001", "value": "88.8", "spread": "5.06"}, {"groupId": "BG002", "value": "88.7", "spread": "6.26"}]}]}]}, {"title": "Platelets", "description": "Measure Description: A CBC panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "THO/uL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "135", "spread": "69.1"}, {"groupId": "BG001", "value": "247", "spread": "63.7"}, {"groupId": "BG002", "value": "241", "spread": "66.2"}]}]}]}, {"title": "Glucose", "description": "A CMP panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "108", "spread": "30.9"}, {"groupId": "BG001", "value": "112", "spread": "49.6"}, {"groupId": "BG002", "value": "110", "spread": "41.3"}]}]}]}, {"title": "Urea Nitrogen", "description": "A CMP panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "20.6", "spread": "7.76"}, {"groupId": "BG001", "value": "10.0", "spread": "7.20"}, {"groupId": "BG002", "value": "20.3", "spread": "7.43"}]}]}]}, {"title": "Creatinine", "description": "A CMP panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.01", "spread": "0.230"}, {"groupId": "BG001", "value": "1.00", "spread": "0.290"}, {"groupId": "BG002", "value": "1.01", "spread": "0.261"}]}]}]}, {"title": "Sodium", "description": "A CMP panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "139", "spread": "2.58"}, {"groupId": "BG001", "value": "129", "spread": "2.07"}, {"groupId": "BG002", "value": "129", "spread": "2.32"}]}]}]}, {"title": "Potassium", "description": "A CMP panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.17", "spread": "0.435"}, {"groupId": "BG001", "value": "4.17", "spread": "0.391"}, {"groupId": "BG002", "value": "4.17", "spread": "0.411"}]}]}]}, {"title": "Chloride", "description": "A CMP panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "101", "spread": "2.59"}, {"groupId": "BG001", "value": "101", "spread": "3.15"}, {"groupId": "BG002", "value": "101", "spread": "2.88"}]}]}]}, {"title": "Carbon dioxide", "description": "A CMP panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28.5", "spread": "2.84"}, {"groupId": "BG001", "value": "28.7", "spread": "3.02"}, {"groupId": "BG002", "value": "28.6", "spread": "2.91"}]}]}]}, {"title": "Anion gap", "description": "A CMP panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.76", "spread": "1.39"}, {"groupId": "BG001", "value": "8.59", "spread": "2.24"}, {"groupId": "BG002", "value": "8.67", "spread": "1.87"}]}]}]}, {"title": "Calcium", "description": "A CMP panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.67", "spread": "0.398"}, {"groupId": "BG001", "value": "9.65", "spread": "0.435"}, {"groupId": "BG002", "value": "9.66", "spread": "0.415"}]}]}]}, {"title": "Protein, total", "description": "A CMP panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.13", "spread": "0.590"}, {"groupId": "BG001", "value": "7.07", "spread": "0.501"}, {"groupId": "BG002", "value": "7.10", "spread": "0.544"}]}]}]}, {"title": "Albumin, total", "description": "A CMP panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.30", "spread": "0.291"}, {"groupId": "BG001", "value": "4.24", "spread": "0.339"}, {"groupId": "BG002", "value": "4.27", "spread": "0.319"}]}]}]}, {"title": "Bilirubin, total", "description": "A CMP panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.590", "spread": "0.241"}, {"groupId": "BG001", "value": "0.564", "spread": "0.195"}, {"groupId": "BG002", "value": "0.577", "spread": "0.218"}]}]}]}, {"title": "Alkaline phophatase", "description": "A CMP panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "U/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "78.5", "spread": "36.4"}, {"groupId": "BG001", "value": "72.3", "spread": "19.4"}, {"groupId": "BG002", "value": "75.3", "spread": "29.0"}]}]}]}, {"title": "AST (aspartate transferase)", "description": "A CMP panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "U/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "20.5", "spread": "7.93"}, {"groupId": "BG001", "value": "24.0", "spread": "11.5"}, {"groupId": "BG002", "value": "22.3", "spread": "10.0"}]}]}]}, {"title": "ALT (alanine transaminase)", "description": "A CMP panel was collected as part of visit labs and processed by our clinical laboratory.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "U/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "19.0", "spread": "8.24"}, {"groupId": "BG001", "value": "22.2", "spread": "13.4"}, {"groupId": "BG002", "value": "20.6", "spread": "11.2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Difference in Peak Oxygen Consumption (Vo2) Between KNO3 and KCl Phases", "description": "Subjects will perform a maximal-effort peak oxygen consumption test using a supine bicycle exercise test with expired gas analysis.", "populationDescription": "As this is a crossover trial, participants received both KNO3 and KCl in different phase, and the sequence of which was dependent on a double blinded randomization. Only participants with outcome data were analyzed. The mean, SD, and t-tests were calculated based on the number of completed cases with successful crossover (N=60), but the mixed model included phase 1 data as well (N=74).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min/kg", "timeFrame": "6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)", "groups": [{"id": "OG000", "title": "Potassium Nitrate (KNO3)", "description": "Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.\n\nPotassium Nitrate (KNO3): The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed."}, {"id": "OG001", "title": "Potassium Chloride (KCl)", "description": "Potassium Chloride (KCl) is the placebo (control drug) in this trial.\n\nPotassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.31714", "spread": "3.851249"}, {"groupId": "OG001", "value": "10.215172", "spread": "3.823188"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "We considered an increase in peak VO2 of \\~0.6 ml/kg/min to be the minimum clinically significant change. Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints with a two-sided \u03b1=0.05. PASS11157 was used to perform power calculations.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6191", "pValueComment": "A two-sided \u03b1=0.05 was determined by the power calculation.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "t = -0.49979, df = 58. N=59 due to analyzing participants with complete data for Phase 1 and Phase 2 that crossovered.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.1309108", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.6552259", "ciUpperLimit": "0.3934043", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.2619326", "estimateComment": "Only participants that successfully crossed over were included in the t-test (N=59)."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "The mixed model analysis provided an assessment of the treatment effect on each continuous outcome of interest while controlling for effects of other covariates such as period, sequence, and a random subject effect.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.711", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "0.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-.043", "ciUpperLimit": "0.62"}]}, {"type": "PRIMARY", "title": "Change in Total Work Performed During a Maximal-effort Exercise Test From Phase 1 to Phase 2", "description": "Subjects will perform a maximal-effort supine bicycle exercise test.", "populationDescription": "Total work was calculated at each phase of the crossover trial. However, the analysis for the t-tests including the reported mean and standard deviation only includes cases in which Phase 1 and Phase 2 were completed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "KJ", "timeFrame": "6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)", "groups": [{"id": "OG000", "title": "Potassium Nitrate (KNO3)", "description": "Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.\n\nPotassium Nitrate (KNO3): The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed."}, {"id": "OG001", "title": "Potassium Chloride (KCl)", "description": "Potassium Chloride (KCl) is the placebo (control drug) in this trial.\n\nPotassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "26.74341", "spread": "32.15162"}, {"groupId": "OG001", "value": "23.76294", "spread": "29.88680"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A two-sided \u03b1=0.05 was determined by the power calculation.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.2871", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "t = 1.0738, df = 62, p-value = 0.2871, N=63 due to analyzing participants with complete data for Phase 1 and Phase 2 that crossovered.", "paramType": "Mean Difference (Final Values)", "paramValue": "2.217657", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.910612", "ciUpperLimit": "6.3459261", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.065196"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "The mixed model analysis provided an assessment of the treatment effect on each continuous outcome of interest while controlling for effects of other covariates such as period, sequence, and a random subject effect. Randomization sequence was not included in the final model due to lack of evidence for a carry over effect. Phase 1 data for participants that did not crossover due to IDS were considered for the model (N=74).", "nonInferiorityType": "SUPERIORITY", "pValue": "0.2935", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "-2.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.12", "ciUpperLimit": "1.88"}]}, {"type": "SECONDARY", "title": "Effect of Potassium Nitrate (KNO3) on Quality of Life (QOL)", "description": "QOL will be assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ). The overall summary score from the KCCQ ranges from 0-100, where higher scores indicate a better quality of life.", "populationDescription": "As this is a crossover trial, participants received both KNO3 and KCl in different phases, the sequence of which was dependent on a double blinded randomization. Only participants with KCCQ results were analyzed. The mean, SD, and t-tests were calculated based on the number of completed cases with successful crossover (N=66), but the mixed model included phase 1 data as well. Baseline scores for all participants were analyzed in the mixed model as a predictive value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)", "groups": [{"id": "OG000", "title": "Potassium Nitrate (KNO3)", "description": "Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.\n\nPotassium Nitrate (KNO3): The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed."}, {"id": "OG001", "title": "Potassium Chloride (KCl)", "description": "Potassium Chloride (KCl) is the placebo (control drug) in this trial.\n\nPotassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial."}, {"id": "OG002", "title": "Baseline", "description": "Prior to randomization"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "71"}, {"groupId": "OG002", "value": "84"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "66.06147", "spread": "18.99883"}, {"groupId": "OG001", "value": "62.77142", "spread": "18.95087"}, {"groupId": "OG002", "value": "61.4335", "spread": "17.02081"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.171", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "t=1.3844, df=65, p=0.171. N=66 due to analyzing participants with complete data for Phase 1 and Phase 2 that crossover correctly.", "paramType": "Mean Difference (Final Values)", "paramValue": "2.1859922", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.9674467", "ciUpperLimit": "5.3392901", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.578944"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "The mixed model analysis provided an assessment of the treatment effect on each continuous outcome of interest while controlling for effects of other covariates such as period, sequence, and a random subject effect.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.113", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "-2.51", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.62", "ciUpperLimit": "0.61"}]}, {"type": "SECONDARY", "title": "Effect of KNO3 on the Percent Change of Systemic Vasodilatory Response to Exercise: The Change in Systemic Vascular Resistance Reserve During Exercise During a Maximal Effort Exercise Test", "description": "We measured the Systematic vasodilatory response at rest and peak maximal exercise using corresponding echo parameters and blood pressures for each visit. This measure depicts the change from rest and exercise.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "% change", "timeFrame": "6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)", "groups": [{"id": "OG000", "title": "Potassium Nitrate (KNO3)", "description": "Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.\n\nPotassium Nitrate (KNO3): The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed."}, {"id": "OG001", "title": "Potassium Chloride (KCl)", "description": "Potassium Chloride (KCl) is the placebo (control drug) in this trial.\n\nPotassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-23.92288", "spread": "23.39527"}, {"groupId": "OG001", "value": "-22.13564", "spread": "24.67150"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.4905", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "t = 0.69507, df=46, p=.4905. N=47 due to only analyzed participants that correctly crossovered.", "paramType": "Mean Difference (Final Values)", "paramValue": "2.776572", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.264221", "ciUpperLimit": "10.817366", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.99464"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "The mixed model analysis provided an assessment of the treatment effect on each continuous outcome of interest while controlling for effects of other covariates such as period, sequence, and a random subject effect.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.796", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "1.088", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.30", "ciUpperLimit": "9.48"}]}, {"type": "SECONDARY", "title": "Effect of Potassium Nitrate (KNO3) on Muscle Phosphocreatine (PCr) Recovery Kinetics Following a Standardized Plantar Flexor Exercise Protocol", "description": "Muscle PCr recovery kinetics were measured using MRI and a standardized plantar flexor exercise protocol with a high resolution spatial mapping of creatine in muscle to analyze creatine chemical exchange saturation transfer and quantify the recovery kinetics of creatine levels. Exercise induces increases in the rate of O2 consumption, which upon cessation of exercise, declines towards baseline in a mono-exponential fashion. This is characterized by a time constant (\u03c4, tau) that corresponds to the time constant of PCr recovery kinetics. Muscle PCr is a marker of oxidative capacity. This outcome measure relates to the half-time derived from linear regression, where a lower value depicts a faster PCr recovery.", "populationDescription": "MRI was not completed throughout the duration of the study and only completed at one site (University of Pennsylvania).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "seconds", "timeFrame": "6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)", "groups": [{"id": "OG000", "title": "Potassium Nitrate (KNO3)", "description": "Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.\n\nPotassium Nitrate (KNO3): The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed."}, {"id": "OG001", "title": "Potassium Chloride (KCl)", "description": "Potassium Chloride (KCl) is the placebo (control drug) in this trial.\n\nPotassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "159.5455", "spread": "99.54442"}, {"groupId": "OG001", "value": "219.8485", "spread": "149.41312"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.4017", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "t=-0.86929,, df=12, p=0.4017", "paramType": "Mean Difference (Final Values)", "paramValue": "-38.11189", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-133.63637", "ciUpperLimit": "57.41259", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "43.84245"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.183", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "61.77", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-34.15", "ciUpperLimit": "157.69"}]}, {"type": "SECONDARY", "title": "Effect of Potassium Nitrate (KNO3) on Left Ventricle (LV) Diastolic Function: E/e' Ratio", "description": "E/e' ratio is a standard echo parameter that was measured at rest during each visit and calculated using the mitral E, septal e', and lateral e'. This index is parameter for noninvasive left ventricular diastolic function assessment, where an E/e' ratio \\< 8 is considered to be normal, and a ratio \\> 15 is considered to reflect an increase in the LV filling pressure.", "populationDescription": "All participants were expected to undergo an echocardiogram at each visit (baseline, Phase 1, and Phase 2).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)", "groups": [{"id": "OG000", "title": "Potassium Nitrate (KNO3)", "description": "Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.\n\nPotassium Nitrate (KNO3): The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed."}, {"id": "OG001", "title": "Potassium Chloride (KCl)", "description": "Potassium Chloride (KCl) is the placebo (control drug) in this trial.\n\nPotassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial."}, {"id": "OG002", "title": "Baseline", "description": "Prior to randomization, a baseline/screening visit was performed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "81"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11.84599", "spread": "3.981865"}, {"groupId": "OG001", "value": "11.61516", "spread": "4.265457"}, {"groupId": "OG002", "value": "11.7999", "spread": "4.48822"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.5636", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "t=0.58074, df=59, p=0.5636", "paramType": "Mean Difference (Final Values)", "paramValue": "0.202782", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.4959279", "ciUpperLimit": "0.9014918", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.202782"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "The mixed model analysis provided an assessment of the treatment effect on each continuous outcome of interest while controlling for effects of other covariates such as period, sequence, and a random subject effect.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.361", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "-0.31180", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.99", "ciUpperLimit": "0.37"}]}, {"type": "SECONDARY", "title": "Effect of Potassium Nitrate (KNO3) on Left Ventricle (LV) Diastolic Function: Left Atrial Volume Index", "description": "Left atrial volume index is a standard echo parameter that was measured at rest during each visit and calculated the body surface area (Dubois and Dubois equation) and left atrial volume from both the two chamber and four chamber views.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/m2", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)", "groups": [{"id": "OG000", "title": "Potassium Nitrate (KNO3)", "description": "Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.\n\nPotassium Nitrate (KNO3): The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed."}, {"id": "OG001", "title": "Potassium Chloride (KCl)", "description": "Potassium Chloride (KCl) is the placebo (control drug) in this trial.\n\nPotassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial."}, {"id": "OG002", "title": "Baseline", "description": "Prior to randomization"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "84"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "26.63060", "spread": "7.812431"}, {"groupId": "OG001", "value": "27.65687", "spread": "9.931385"}, {"groupId": "OG002", "value": "27.4408", "spread": "8.92840"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.7707", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "t= -0.29271, df=61, p=0.7707", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.1532142", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.1998786", "ciUpperLimit": "0.8934502", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "-0.1532142"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "The mixed model analysis provided an assessment of the treatment effect on each continuous outcome of interest while controlling for effects of other covariates such as period, sequence, and a random subject effect.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.724", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "0.18872", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.88", "ciUpperLimit": "1.25"}]}, {"type": "SECONDARY", "title": "Effect of Potassium Nitrate (KNO3) on Myocardial Systolic Strain: Peak Global Systolic Myocardial Longitudinal Strain", "description": "Peak global systolic myocardial longitudinal strain was evaluated with resting echocardiograms at each visit. Strain was analyzed at the four chamber, two chamber, and three chamber views of the left ventricle and averaged.", "populationDescription": "All participants underwent an echocardiogram at each visit; however, participants in which these echo measures could not be reliably quantified were excluded.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "% (change in length)", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)", "groups": [{"id": "OG000", "title": "Potassium Nitrate (KNO3)", "description": "Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.\n\nPotassium Nitrate (KNO3): The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed."}, {"id": "OG001", "title": "Potassium Chloride (KCl)", "description": "Potassium Chloride (KCl) is the placebo (control drug) in this trial.\n\nPotassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial."}, {"id": "OG002", "title": "Baseline", "description": "Prior to randomization/first visit"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18.04317", "spread": "2.812165"}, {"groupId": "OG001", "value": "17.273221", "spread": "3.003472"}, {"groupId": "OG002", "value": "17.7164", "spread": "2.289224"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.1680825", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "t=1.3983, df=51, p=0.1681", "paramType": "Mean Difference (Final Values)", "paramValue": "0.3262821", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.1421806", "ciUpperLimit": "0.7947447", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.2333465"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0930", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "-0.4082", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.88", "ciUpperLimit": "0.07"}]}, {"type": "SECONDARY", "title": "Effect of Potassium Nitrate (KNO3) on Late Systolic Wall Stress as Assessed by the Arts Formula Using Echocardiographic and Tonometry Recordings", "description": "Late systolic wall stress is assessed via comprehensive aortic pressure-flow relations, using arterial tonometry and Doppler echocardiography. Myocardial wall stress was calculated with the following formula =: Stress = P / \\[1/3 In (1 + VW/VLV)\\], where ln is the natural logarithm, P is aortic pressure obtained with arterial tonometry, VW is the volume of the LV wall obtained with echocardiography and VLV is the cavity volume obtained with echocardiography", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "dynes\u00b7cm-2\u00b7s", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)", "groups": [{"id": "OG000", "title": "Potassium Nitrate (KNO3)", "description": "Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.\n\nPotassium Nitrate (KNO3): The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed."}, {"id": "OG001", "title": "Potassium Chloride (KCl)", "description": "Potassium Chloride (KCl) is the placebo (control drug) in this trial.\n\nPotassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial."}, {"id": "OG002", "title": "Baseline", "description": "Prior to randomization/first visit"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "57"}, {"groupId": "OG002", "value": "70"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "32.36347", "spread": "7.464010"}, {"groupId": "OG001", "value": "34.31358", "spread": "7.837627"}, {"groupId": "OG002", "value": "33.95494", "spread": "7.746475"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.07984", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.116437", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.4966754", "ciUpperLimit": "0.2638017", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.176768", "estimateComment": "t = -1.7985, df=39, p=0.07984"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.135", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "1.68", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.54", "ciUpperLimit": "3.90"}]}, {"type": "SECONDARY", "title": "Effect of Potassium Nitrate (KNO3) on Arterial Wave Reflections as Assessed by Wave Separation Analysis Using Tonometry and Doppler Flow Data", "description": "Arterial Wave reflections were assessed via wave separation analysis, using arterial tonometry and Doppler echocardiography.\n\nThe pulse wave generated by the left ventricle travels forward in arteries and is partially reflected at sites of impedance mismatch (i.e., bifurcations, points of change in arterial size or wall stiffness, predominantly in middle-sized conduit arteries). Wave reflections travel back to the heart, merging into a discrete reflected wave and arrive while the LV is still ejecting blood in mid-to-late systole. Wave reflections increase the late systolic workload of the LV and profoundly impact the LV loading sequence (late relative to early systolic load).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "unitless", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)", "groups": [{"id": "OG000", "title": "Potassium Nitrate (KNO3)", "description": "Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.\n\nPotassium Nitrate (KNO3): The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed."}, {"id": "OG001", "title": "Potassium Chloride (KCl)", "description": "Potassium Chloride (KCl) is the placebo (control drug) in this trial.\n\nPotassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial."}, {"id": "OG002", "title": "Baseline", "description": "Prior to randomization/first visit"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "57"}, {"groupId": "OG002", "value": "70"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.3681837", "spread": "0.08317293"}, {"groupId": "OG001", "value": "0.372307", "spread": "0.0786807"}, {"groupId": "OG002", "value": "0.3804", "spread": "0.07106"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.1450", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.0192733", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.0454871", "ciUpperLimit": "0.00694040", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.01295984"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.3047", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "0.01324", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.01", "ciUpperLimit": "0.04"}]}, {"type": "SECONDARY", "title": "Effect of Potassium Nitrate (KNO3) on Augmentation Index", "description": "Aortic augmentation index was assessed via comprehensive aortic pressure-flow relations, using arterial tonometry and Doppler echocardiography. It is an indirect measure of arterial stiffness, where a higher value would indicate greater arterial stiffness risk.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Index", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)", "groups": [{"id": "OG000", "title": "Potassium Nitrate (KNO3)", "description": "Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.\n\nPotassium Nitrate (KNO3): The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed."}, {"id": "OG001", "title": "Potassium Chloride (KCl)", "description": "Potassium Chloride (KCl) is the placebo (control drug) in this trial.\n\nPotassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial."}, {"id": "OG002", "title": "Baseline", "description": "Prior to randomization/Visit 1"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "57"}, {"groupId": "OG002", "value": "70"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "122.6139", "spread": "25.40388"}, {"groupId": "OG001", "value": "122.5160", "spread": "28.58736"}, {"groupId": "OG002", "value": "126.3574", "spread": "26.08744"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.44", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.506681", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.598617", "ciUpperLimit": "5.585256", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.494971"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.39911", "pValueComment": "Assuming a 90% retention rate, enrolling 84 subjects in this cross-over trial will have 80% power to detect such an effect size in the intervention induced change of our study endpoints, with a two-sided \u03b1=0.05.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "3.39106", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.66", "ciUpperLimit": "11.44"}]}, {"type": "SECONDARY", "title": "Effect of Potassium Nitrate (KNO3) on Muscle Blood Flow During Exercise: Muscle Blood Flow During Exercise, Measured With Arterial MRI Spin Labeling During a Standardized Plantar Flexion Exercise Test", "description": "MRI studies will be performed at rest and immediately after a standardized plantar flexion exercise. Arterial spin labeling using the flow-sensitive alternating inversion recovery (FAIR) technique will be used to image muscle perfusion with high temporal resolution.", "populationDescription": "Analysis could not be performed as the MRI studies were not able to extract this measure.", "reportingStatus": "POSTED", "timeFrame": "6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)", "groups": [{"id": "OG000", "title": "Potassium Nitrate (KNO3), Then Potassium Chloride (KCl)", "description": "Potassium nitrate (KNO3) capsules, provided 6 millimoles of inorganic nitrate per capsule, and was taken three times daily for 6 weeks.\n\nAfter a one week washout period, participants crossed over to take Potassium Chloride.\n\nPotassium Chloride (KCl) capsules was administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial."}, {"id": "OG001", "title": "Potassium Chloride (KCl) Then Potassium Nitrate (KNO3)", "description": "Potassium Chloride (KCl) capsules was administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial.\n\nPotassium Nitrate (KNO3) capsules, provided 6 millimoles of inorganic nitrate per capsule, and was taken three times daily for 6 weeks.\n\nAfter a one week washout period, participants crossed over to take Potassium Nitrate."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Effect of Potassium Nitrate (KNO3) on Myocardial Systolic Strain: Peak Global Systolic Myocardial Circumferential Strain", "populationDescription": "Peak Global Systolic Myocardial Circumferential Strain was not analyzed in the echocardiogram as this measure was not quantified at all during the study; instead, other strain measurements were evaluated alternatively that are considered to be more reliable.", "reportingStatus": "POSTED", "timeFrame": "All three visits: Baseline (first) visit; 6 weeks after start of phase 1 (experimental drug or control); 6 weeks after start of phase 2 (experimental drug or control)", "groups": [{"id": "OG000", "title": "Potassium Nitrate (KNO3), Then Potassium Chloride (KCl)", "description": "Potassium nitrate (KNO3) capsules, provided 6 millimoles of inorganic nitrate per capsule, and was taken three times daily for 6 weeks.\n\nAfter a one week washout period, participants crossed over to take Potassium Chloride.\n\nPotassium Chloride (KCl) capsules was administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial."}, {"id": "OG001", "title": "Potassium Chloride (KCl) Then Potassium Nitrate (KNO3)", "description": "Potassium Chloride (KCl) capsules was administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial.\n\nPotassium Nitrate (KNO3) capsules, provided 6 millimoles of inorganic nitrate per capsule, and was taken three times daily for 6 weeks.\n\nAfter a one week washout period, participants crossed over to take Potassium Nitrate."}, {"id": "OG002", "title": "Baseline", "description": "Prior to randomization/first visit"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse events were collected for each participant starting on their baseline visit to 6 weeks per intervention with 1 week wash-out between, up to 13 weeks", "description": "Total number at risk for baseline column is total number of participants at risk during the baseline visit including participants who screen failed (screen fail participants still attended a baseline visit). These events happened prior to randomization.\n\nTotal number at risk for either KCl or KNO3 refers to the total number of participants randomized to medication or placebo respectively at risk for an AE.", "eventGroups": [{"id": "EG000", "title": "Potassium Nitrate (KNO3)", "description": "Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.\n\nPotassium Nitrate (KNO3): The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed.", "deathsNumAffected": 0, "deathsNumAtRisk": 77, "seriousNumAffected": 1, "seriousNumAtRisk": 77, "otherNumAffected": 43, "otherNumAtRisk": 77}, {"id": "EG001", "title": "Potassium Chloride (KCl)", "description": "Potassium Chloride (KCl) is the placebo (control drug) in this trial.\n\nPotassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks.\n\nPotassium Chloride (KCl): Potassium Chloride (KCl) is the matching placebo control drug in this trial.", "deathsNumAffected": 0, "deathsNumAtRisk": 74, "seriousNumAffected": 1, "seriousNumAtRisk": 74, "otherNumAffected": 45, "otherNumAtRisk": 74}, {"id": "EG002", "title": "Baseline Visit", "description": "At the baseline visit, patients were not on IP, but participants were monitored and consented in the study.\n\nAll participants were at risk during their baseline visit, even the screen fails.\n\nEvents include events that occurred in participants who were not randomized as well as those who were randomized.", "deathsNumAffected": 0, "deathsNumAtRisk": 84, "seriousNumAffected": 1, "seriousNumAtRisk": 84, "otherNumAffected": 61, "otherNumAtRisk": 84}], "seriousEvents": [{"term": "abnormal sensation of swallowing", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "aches in the joints", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "acute exacerbation of bronchiectasis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "atrial fibrillation", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "belching", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "bilateral knee pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "bloating", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "blurred vision", "organSystem": "Eye disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "bronchitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "calves aching", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "chest pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "cramps", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "creatinine increase", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "diarrhea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "dizziness", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "edema", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "fatigue", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "fever", "organSystem": "Immune system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "flu", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "gassiness", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "headache", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "hip pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "hypoglycemic episode", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "increased stomach acid", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "insomnia", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "leg cramps", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "lightheadedness", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "lower back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "hypoxemia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "nasal discharge", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "nervousness", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "o2 desaturation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "oral thrush", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "palpitations", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "positive orthostat", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "rapid heart beat", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "restlessness", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "shortness of breath", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "shortness of breath during the peak exercise test", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "sinus infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "skin irritation", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "sore throat", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "soreness", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "stomach ache", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "swelling", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "thigh cramps", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "vomiting", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "weakness", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "fatigue during the peak exercise test", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "other", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}], "otherEvents": [{"term": "abnormal sensation of swallowing", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "aches in the joints", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "acute exacerbation of bronchiectasis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "atrial fibrillation", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "belching", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "bilateral knee pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "bloating", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "blurred vision", "organSystem": "Eye disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "bronchitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "calves aching", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "chest pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 84}]}, {"term": "cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "cramps", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "creatinine increase", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "diarrhea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 4, "numAffected": 3, "numAtRisk": 84}]}, {"term": "dizziness", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "edema", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "fatigue", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 11, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 6, "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 84}]}, {"term": "fever", "organSystem": "Immune system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "flu", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "gassiness", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "headache", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 84}]}, {"term": "hip pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "hypoglycemic episode", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "increased stomach acid", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "insomnia", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "leg cramps", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 84}]}, {"term": "lightheadedness", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 84}]}, {"term": "lower back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "hypoxemia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "nasal discharge", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 84}]}, {"term": "nervousness", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "o2 desaturation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "oral thrush", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "palpitations", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "positive orthostat", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "rapid heart beat", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "restlessness", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "shortness of breath", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 7, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 84}]}, {"term": "shortness of breath during the peak exercise test", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "sinus infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 84}]}, {"term": "skin irritation", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "sore throat", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "soreness", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "stomach ache", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 15, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 8, "numAffected": 7, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 7, "numAffected": 7, "numAtRisk": 84}]}, {"term": "swelling", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}]}, {"term": "thigh cramps", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "vomiting", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 84}]}, {"term": "weakness", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "fatigue during the peak exercise test", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}]}, {"term": "other", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 29, "numAffected": 16, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 22, "numAffected": 17, "numAtRisk": 74}, {"groupId": "EG002", "numEvents": 19, "numAffected": 12, "numAtRisk": 84}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Due to dispensing errors, nine participants didn't crossover. Overall study power was maintained. MRI completion varied across sites, leading to the discontinuation of this study component. MRI endpoints have a smaller N; interpret results cautiously. Myocardial circumferential strain wasn't quantified. Instead, longitudinal LV function, crucial for LV relaxation and filling, was quantified."}, "certainAgreement": {"piSponsorEmployee": true, "restrictiveAgreement": false}, "pointOfContact": {"title": "Hannah Maynard", "organization": "University of Pennsylvania", "email": "hannah.maynard@pennmedicine.upenn.edu", "phone": "215-662-7580"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2021-10-07", "uploadDate": "2023-07-20T14:06", "filename": "Prot_SAP_000.pdf", "size": 1895714}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2022-01-07", "uploadDate": "2023-07-20T14:07", "filename": "ICF_001.pdf", "size": 802100}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}